NYSE:ABBVBiotechs
Assessing AbbVie (ABBV) Valuation After New US$380 Million Facilities And Positive Skyrizi Crohn’s Data
AbbVie (ABBV) has just paired two meaningful updates: a US$380 million build out of new Illinois API facilities and positive Phase 3 Crohn's data for Skyrizi, giving investors fresh information on both capacity and pipeline.
See our latest analysis for AbbVie.
Against this backdrop of new clinical and manufacturing updates, AbbVie’s share price has had a mixed few months, with a 5.99% 30 day share price return and a much stronger 157.47% five year total shareholder return, suggesting that...